{"algorithm_version": "v0.5.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["2026-09-01: Medtronic reported fiscal Q1 2027 results with revenue of $9.756 billion, up 13.7% year over year, and adjusted EPS of $1.45, both ahead of expectations.", "2026-09-01: Management raised fiscal 2027 guidance, lifting organic revenue growth outlook to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00.", "Strong Q1 2027 earnings beat and revenue growth of 13.7%.", "Management raised guidance for both revenue and earnings for the year.", "Medtronic beat earnings estimates with $9.76B in revenue, up 13.7% year over year, and raised its full-year profit guidance."], "company_name": "Medtronic", "conviction": "high", "data_quality": 0.9, "date": "2026-09-02", "favorable_models_count": 3, "final_confidence": 0.8177772193709991, "final_score": 86.04066666666667, "generated_at": "2026-09-02T06:30:00.006722-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 75.31, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The stock may give back gains if investors focus on forward risks rather than the beat, including foreign exchange pressure and execution risk on growth initiatives.", "The current move may already price in the earnings surprise, creating a post-earnings fade risk.", "Premarket gap and high trading volume may lead to profit-taking.", "Negative average news sentiment could temper enthusiasm.", "The premarket gap has already priced in much of the good news, leaving room for a 'buy the rumor, sell the news' pullback."], "shortfalls": [], "status": "signal", "summary": "Medtronic has a clear near-term bullish setup after a strong fiscal Q1 2027 earnings beat, a guidance raise, and an FDA clearance announced on 2026-09-01. In the next US session, the main stock movers are likely to be follow-through buying from the earnings surprise and guidance increase, versus possible profit-taking if traders decide the good news is already reflected in the premarket move.", "ticker": "MDT", "timezone": "Europe/Zurich", "watchlist": []}